Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

The study, led by Dr Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that ...

In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...

Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

A new study reveals that taking tirzepatide once a week can lead to significant and long-lasting weight loss for up to three ...

Among 282 adults with inadequately controlled type 2 diabetes despite treatment ... primary endpoint in other SURPASS phase III studies," they said. Both the tirzepatide and dulaglutide groups ...

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

For patients with inadequately controlled T2D receiving dulaglutide, switching to tirzepatide is associated with additional HbA1c reduction and weight loss.

Researchers have found in a new research that among patients with poorly controlled type 2 diabetes, switching from ...